GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: FF via ELLIPTA DPIDrug: FF/VI via ELLIPTA DPI
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 906
- Registration Number
- NCT03248128
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults
Phase 1
Terminated
- Conditions
- Pancreatitis, Acute Necrotizing
- Interventions
- Drug: GSK3335065Drug: Placebo
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT03245619
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 1
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: CCI15106 7.5 mg capsuleDrug: PlaceboDrug: Placebo-2
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT03243760
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Injury and Healthy Participants
Phase 1
Terminated
- Conditions
- Burns
- Interventions
- Other: Lactulose and Mannitol solutionOther: Sucralose
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT03242434
- Locations
- 🇬🇧
GSK Investigational Site, Birmingham, United Kingdom
Absorption and Elimination of Radiolabeled Daprodustat
Phase 1
Completed
- Conditions
- Anaemia
- Interventions
- Drug: [14C]-GSK1278863 solution for IV infusionDrug: [14C]-GSK1278863 oral solutionDrug: Daprodustat 6 mg oral tablet
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03239522
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
Phase 2
Withdrawn
- Conditions
- Autoimmune Diseases
- Interventions
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03239600
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
Phase 2
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 89
- Registration Number
- NCT03238352
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDrug: CCI15106
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT03235726
- Locations
- 🇬🇧
GSK Investigational Site, Park Royal, London, United Kingdom
A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: GSK2838232 100 mg tabletDrug: Placebo for GSK2838232 tabletsDrug: GSK2838232 50 mg capsuleDrug: Ritonavir 100 mg tablets
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03234036
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Experimental Daily Defense Serum GOther: Experimental Daily Defense Serum AOther: Experimental Daily Defense Serum COther: Experimental Daily Defense Serum NOther: Saline Solution Sodium Chloride
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 43
- Registration Number
- NCT03233009
- Locations
- 🇧🇷
GSK Investigational Site, Valinhos, Brazil
© Copyright 2025. All Rights Reserved by MedPath